RudaCure is also actively pursuing global market entry. The company established an overseas subsidiary in 2021 and participates in major pharmaceutical/bio exhibition partnering events such as JPM, Bio-Europe, and Bio-USA to attract overseas investment and technology transfers. The company is also engaged with overseas accelerators including KIC (Korea Innovation Center), the U.S. Mass Challenge program, and the Shinhan Square Bridge Global Program, as well as U.S. bio events including UKC2022 and the RESI Conference. Most recently, the company won awards at IR competitions at UKC2022 (Washington D.C.) and RESI Conference (Boston).
Regarding future plans, CEO Kim stated, "We will advance RCI001 domestic Phase 1 clinical trials within this year," adding, "Our goal is to proceed with U.S. FDA Phase 2 clinical trials by the first half of 2023."
Founded: July 2018
Main business: New drug development including dry eye disease and chronic pain treatments
Achievements: Certified corporate R&D center (2019.1), Certified venture company (2019.5), Technology-innovative SME certification (2022.3), Ministry of Employment and Labor Strong Small Enterprise designation (2022.05). RCI001 dry eye treatment: 1 patent application + 2 patents registered; RCI002 chronic pain treatment: 5 patent applications + 1 patent registered; 2 joint development patents registered; 2 trademark registrations; KRW 15 billion joint R&D agreement with Hanlim Pharmaceutical; KRW 6 billion Series A investment completed (2022.5); RudaCure U.S.A. incorporated (2021.08); Expanded to dual Songdo HQ and Seoul branch structure (2022.07); 2022 Korean-American Scientists Conference SBA Award; RESI Conference pitch competition award winner
📊 Related Materials & Evidence
[Patent certificate image slot]Patent Registration Certificate (RCI001)
[Event photo image slot]RESI Conference on-site
🔗 Related Links: